Member Info for Sangijuelas1

AACR have featured updates on liquid biopsies for the last few years.

For example, here were the topics covered last year.

https://www.aacr.org/blog/2023/08/31/the-expanding-potential-of-liquid-biopsy-to-detect-and-monitor-cancer/#:~:text=At%20the%20AACR%20Annual%20Meeting,without%20chemical%20or%20enzymatic%20treatment.

Liquid biopsy could involve CTCs but also CTdna, CFdna and extra cellular vassicles.

There are a lot of companies pushing a lot of products and they all think theirs is best.

This is why I am here.

To challenge misinformation.

You get called out by Bantham and 10 minutes later you are doing it again.

There you go again Tom. A pointless post by the Snake Ophidian and you are spreading fake news again.

There is no indication whatsoever that the reference to Liquid Biopsy at AACR has anything to do with Angle.

Absolutely none. There are dozens of companies doing liquid biopsy and I am pretty sure the developments will be involving CTdna rather than anything Angle have done.

Thanks Bantham. I was tempted earlier after being kicked in the head by a horse but your post stopped me in my tracks!

A pharmaceutical company is not going to buy a medical testing company.

They serve different markets.

Clueless.com

Because of a speculative bubble in biotechs that burst shortly after.

What are the catalysts?

That's because the shares were placed at the peak of a speculative bubble.

Investors don't want potential now.

They are like show me the money.

The thing is you can't take them seriously. They said the same about many multiples of the SP for a buyout when it was 150p.

Who is going to pay £200m for a revenue of £6m?

It is cleared as a novel device to capture intacts CTCs in MBC to a standard that the FDA are satisfied with.

It is currently labelled for Research Use only because by itself it can only be used for research.

How it is used in future depends on who runs trials to assess it's use as a clinical diagnostic.

Research use only covers pharma drug trials so it does have a commercial use with both products and services.

None of my posts have been deleted.

I said Parsortix was cleared by the FDA as a novel device to capture CTCs for further analysis.

I don't dispute that Angle can offer service solutions in house to pharma companies for trials.

The point is it is only approved for MBC if clinicians want to build a diagnostic test using it.

Two separate things

Some companies are already using the Cellsearch system for this and also CTdna.

Neither of these are ideal but it is hard to get people to change their ways sometimes.

Hence Angle's efforts to "educate" the market.

OK I acknowledge that it's on the slide.

But they still aren't all HER2 trials, which is what the Portrait assay is being used for

Also if the Eisai trial has 208 participants and they are charging £5k why is the current contract only £250k

Eisai do not have 60k oncology patients in trials.

The trial is for the use of the specific Portrait HER2 assay so would only apply to other drugs Eisai have targeting HER2.

Stop lying

Taken another look at the Eisai trial. Notably it involves not only Parsortix but the Portrait HER2 assay.

I think the reference to multiple clinical trials that could use the Portrait HER2 assay, they mean other companies taking an interest.

So while they may get repeat business from Eisai, it's more the case that they hope to target business from other companies with similar HER2 targeting drugs.

The high sales of the drug Enhertu for breast cancer has led other companies like Eisai and BionTech to try and find similar candidates.

BionTech so far only seem to have used CTdna to screen patients for their trials.

There are some other companies so the hope is that this will lead to the multiple clinical trials.

I mean it just shows the riff raff Angle attracts.

I can only compare to the recent GROW presentation I attended which required a bow tie.

Were you the one wearing the hoodie?

Unfortunately women are not really my bag.

This is your bag though. Hold it tight!

Some of us investors don't stop at 4.30.

Not when US markets are open for another 4.5 hours.

Lot of better apps there than on the moribund UK market!